Valuation: GENFIT

Market Cap 679M 773M 634M 582M 1.09B 74.05B 1.12B 7.52B 2.94B 36.64B 2.9B 2.84B 127B P/E 2026 *
35x
P/E 2027 * 90.2x
Enterprise Value 628M 715M 586M 538M 1.01B 68.48B 1.03B 6.95B 2.72B 33.89B 2.68B 2.63B 117B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 4.94x
Free-Float
86.88%
Yield 2026 *
-
Yield 2027 * -
1 day+2.12%
Current month+56.75%
1 month+56.75%
3 months+49.24%
6 months+160.46%
Current year+157.28%
1 month 13.14
Extreme 13.14
13.7
Current year 5.2
Extreme 5.205
13.7
1 year 3.19
Extreme 3.19
13.7
3 years 3.19
Extreme 3.19
13.7
5 years 3.19
Extreme 3.19
13.7
10 years 3.19
Extreme 3.19
13.7
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
+3.01%0.00% - - 773M
-0.80%+5.16%-0.70%+12.87% 48.95B
-4.10%+14.02%+23.42%+5.64% 40.75B
+3.48%-0.89%+405.39%+612.65% 38.46B
-2.29%-2.75%+5.95%+48.35% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-1.17%-2.05% - - 16.62B
-1.17%-5.10%+31.33%+127.10% 16.33B
-5.31%-1.98%-8.02%-33.60% 13.65B
-0.06%+3.75%+3.81%+9.62% 13.56B
Average -0.32%+6.06%+59.10%+104.27% 28.13B
Weighted average by Cap. -0.30%+7.20%+74.05%+124.28%

Financials

2026 *2027 *
Net sales 100M 114M 93.53M 85.83M 161M 10.92B 165M 1.11B 434M 5.4B 428M 419M 18.68B 124M 141M 116M 106M 199M 13.52B 204M 1.37B 537M 6.69B 530M 519M 23.13B
Net income 22.88M 26.04M 21.35M 19.6M 36.69M 2.49B 37.59M 253M 99.03M 1.23B 97.75M 95.63M 4.27B 6.8M 7.74M 6.35M 5.83M 10.9M 741M 11.17M 75.27M 29.43M 367M 29.05M 28.42M 1.27B
Net Debt -51.12M -58.17M -47.71M -43.79M -81.97M -5.57B -83.99M -566M -221M -2.76B -218M -214M -9.53B -66.17M -75.31M -61.77M -56.69M -106M -7.21B -109M -732M -286M -3.57B -283M -277M -12.34B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.58EUR
Average target price
15.90EUR
Spread / Average Target
+17.08%

Quarterly revenue - Rate of surprise